Evidence map›Paper›PMID 40673078›Full record

ArticleTranslational lung cancer research2025

Assessing the clinical impact of severe lung cancer on non-small cell lung cancer: a single-center retrospective study.

Huixin Jiang, Ling Yi, Du Feng, Hao Deng, Qiexinhao Li, Wenhui Guan, Yue Zhu, Yijia Li, Bin He, Gengda Huang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Huixin Jiang *Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Ling Yi *Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Du Feng *Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Hao Deng *Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Qiexinhao Li *Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wenhui GuanDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yue ZhuDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yijia LiDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Bin HeDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Gengda HuangDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Ying WuDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xinqing LinDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Chengzhi ZhouDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Severe lung cancer (SLC) refers to patients with performance status (PS) ranging from 2 to 4, who may show improvement through the resolution of life-threatening but treatable factors, including comorbidities, tumor-related complications, and treatment-related advanced events. This concept has gained international expert consensus but remains underexplored, especially in the context of non-small cell lung cancer (NSCLC). This study specifically aims to clarify the association between critical status (CS), SLC and survival outcomes, providing insight into the clinical significance of SLC in NSCLC management. Methods: The retrospective study enrolled 254 NSCLC patients from the First Affiliated Hospital of Guangzhou Medical University. These patients were divided into three groups: stable population group, SLC, and non-SLC. Kaplan-Meier method and log-rank test were used to estimate overall survival (OS, primary endpoint). Cox regression analyses were performed to identify variables associated with OS. Additionally, correlation analysis was conducted to explore relationships between various variables and the progression of CS. Results: Sixty-one (24.0%) out of 254 patients met initial CS during their clinical course. Forty-one (67.2%) out of 61 patients recovered after definite therapy, identified as SLC. Median follow-up was 19.4 months. No significant difference was observed in baseline characteristics between stable population and those who met CS. Developing CS was independent risk factor related to OS after cox regression analyses [hazard ratio (HR), 21.9; 95% confidence interval (CI): 6.6-73.8; P<0.001]. Both SLC (HR, 5.4; 95% CI: 1.2-24.3; P=0.03) and non-SLC (HR, 101.2; 95% CI: 23.2-441.6; P<0.001) were also independently associated with worse OS. The median OS of CS population (44.3 months; 95% CI: 20.2-68.5) was significantly worse than that of the stable population (P<0.001). Among patients who developed CS, SLC had a significantly longer median OS compared with non-SLC (P<0.001). Survival was significantly worse in the SLC population compared to the stable population (P=0.01). Correlation analysis showed a significant negative correlation between supportive therapy and CS progression. Significant differences were observed between the SLC and non-SLC groups regarding gender distribution (P=0.03) and the use of first-line ICI-based therapy (P=0.02). Conclusions: The occurrence of initial CS significantly impairs OS in NSCLC patients. However, therapeutic interventions targeting the underlying causes of SLC can improve OS. These findings underscore the importance of early identification and management of CS in NSCLC patients. Further well-designed studies are warranted to validate these results and explore optimal treatment strategies for this patient population.

Indexed as

clinical impactNon-small cell lung cancer (NSCLC)severe lung cancer (SLC)

Identifiers

PMID40673078
PMCPMC12261244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.